摘要
在我国，前列腺癌发病率逐年上升，晚期前列腺癌首选内分泌治疗，但相当一部分患者在内分泌治疗2-5年后病情进展为激素抵抗型前列腺癌（HRPC）。现就HRPC的分子生物学特点诊断标准、预测指标和治疗方法的研究进展作一综述，并展望HRPC的研究方向。
In China, the incidence of prostate cancer has been increasing in recent years. Hormonal therapy has been the mainstay of the therapeutic options for metastatic diseases for many years. But many metastatic tumors progress at a median of two to five years and become hormonal refractory prostate cancer（HRPC）. This article summarizes in the advances of diagnostic criteria, molecular biological features, prediction markers, new therapeutic agents and further researches to be undertaken concerning HRPC.
出处
《中华男科学杂志》
CAS
CSCD
2007年第1期57-60,共4页
National Journal of Andrology
关键词
前列腺癌
激素抵抗型
诊断
治疗
prostate cancer
hormonal refractory
diagnosis
treatment
